Johnson Investment Counsel’s TG Therapeutics TGTX Stock Holding History

Johnson Investment Counsel’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$451K	Hold	8,212	–	–	﹤0.01%	641
2026 Q1	$273K	Hold	8,212	–	–	﹤0.01%	730
2025 Q4	$245K	Buy	+8,212	New	+$268K	﹤0.01%	722
2023 Q4	–	Sell	-17,862	Closed	-$149K	–	737
2023 Q3	$149K	Sell	17,862 -46	-0.3%	-$641	﹤0.01%	650
2023 Q2	$445K	Buy	17,908 +46	+0.3%	+$1.19K	0.01%	493
2023 Q1	$269K	Hold	17,862	–	–	﹤0.01%	575
2022 Q4	$211K	Hold	17,862	–	–	﹤0.01%	616
2022 Q3	$106K	Hold	17,862	–	–	﹤0.01%	627
2022 Q2	$76K	Buy	+17,862	New	+$112K	﹤0.01%	636

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Johnson Investment Counsel's TGTX Position: Q2 2026 in Review

Johnson Investment Counsel held its TG Therapeutics (TGTX) position steady in Q2 2026 at 8,212 shares worth $451K. The position accounts for ﹤0.01% of the portfolio, ranked #641.

Johnson Investment Counsel first reported a position in TGTX in Q2 2022 and has held it in 9 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Johnson Investment Counsel held 8,212 shares of TG Therapeutics worth $451K as of Q2 2026.
Johnson Investment Counsel left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up ﹤0.01% of Johnson Investment Counsel's portfolio in Q2 2026, its #641 holding.
Johnson Investment Counsel first reported a position in TG Therapeutics in Q2 2022 and has held it in 9 quarters since.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.